吲哚布芬对急性脑梗死治疗的临床分析.docVIP

吲哚布芬对急性脑梗死治疗的临床分析 杨琨 孙佳凡 山西省中西医结合医院神经内科 Clinic Analysis of Treatment on the Acute Ischemic Stroke with Indobufen Yang-kun Sun-jiafan Department of Neurology,Shanxi Provincial Hospital of Integrated Traditional Chinese and Western Medicine，Taiyuan 030013,China;〔Abstract〕Objective To investigate the effects and safety of Xinbei- indobufen in patients with acute chemic stroke disease. Methods 170 patients with acute ischemic stroke were selected and randomly divided into experiment group (n=82) and control group (n=88). The patients in experiment group were given anti-platelet indobufen (200mg, bid) and others in control group were given aspirin (100mg, qd) for 6 weeks. Platelet aggregation, the score of neurology impairment and adverse effects were compared between the two groups. Results: After treatment, the platelet aggregation in both groups were lower at 2-week and 6-weeks than before (P0.01). The score of neurology impairment in the both groups were improved at the 6-weeks (P0.01). There was no significant difference in the platelet aggregation and the score between experiment group and control group (P0.05).Drug related serious adverse effects were not found in the experiment group. Conclusion Indobufen may reduce significantly platelet aggregation on the patients with acute ischemic stroke. The effect on anti-platelet of indobufen was equal to one of aspirin. Indobufen related adverse effects were seldom and minor. Indobufen was safe in treating acute ischemic stroke. Key words: Indobufen, anti-platelet, acute ischemic stroke 摘要：目的 探讨吲哚布芬治疗急性脑梗死患者的临床疗效。方法 入选的170例急性脑梗死患者随机分为试验组（n=82）和阳性药物对照组（n=88），试验组给予吲哚布芬治疗，对照组给予阿司匹林治疗，余治疗同急性脑梗死常规治疗。对两组治疗前后血小板聚集率、临床症状和不良反应发生率进行比较。结果 试验组、对照组治疗后14天、6周时血小板聚集率均显著低于治疗前（P0.01）；两组在治疗后神经功能缺损评分均有显著性好转（P0.01）；两组间治疗后血小板聚集率、临床疗效无明显差别（P0.05）；试验组未出现严重的不良反应。结论 吲哚布芬能显著降低血小板聚集率，与阿司匹林相当，在脑梗死急性期时使用安全性高。 关键词：吲哚布芬，抗血小板，急性脑梗死 脑梗死是高发病率，高致残率和高致死率的疾病，对于缺血性脑梗死，抗血小板药物是治疗缺血性脑血管病的基石。目前多采用阿司匹林基础上联合氯吡格雷抗血小板治疗，但随着“阿司匹林抵抗”以及不能耐受阿司匹林的现象被关注，越来越多的研究在探索新的抗血小板药物